Classic Mediterranean Kaposi's sarcoma regression with sirolimus treatment

Archives of Dermatology

Volumn 144, Issue 5, 2008, Pages 692-693

  Guenova, Emmanuella ^a   Metzler, Gisela ^b   Hoetzenecker, Wolfram ^b   Berneburg, Mark ^b   Rocken, Martin ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BIOLOGICAL MARKER; EOSIN; HEMATOXYLIN; MONOCLONAL ANTIBODY D2-40; ONCOFETAL ANTIGEN; RAPAMYCIN;

ABSENCE OF SIDE EFFECTS; ADULT; ANAMNESIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CASE REPORT; CRYOTHERAPY; DRUG BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPOSI SARCOMA; LETTER; LYMPH VESSEL ENDOTHELIUM; MALE; MONOTHERAPY; PRIORITY JOURNAL; RASH; TREATMENT DURATION;

ANTIBIOTICS, ANTINEOPLASTIC; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; SARCOMA, KAPOSI; SIROLIMUS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 44249102076     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.144.5.692     Document Type: Letter

References (5)

1. Boeckle E, Boesmueller C, Wiesmayr S, et al. Kaposi sarcoma in solid organ transplant recipients: a single center report. Transplant Proc. 2005;37(4):1905-1909.
2. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renaltransplant recipients. N Engl J Med. 2005;352(13):1317-1323.
3. Weenink JJ, Groeneveld JO, de Fijter CW. Sirolimus monotherapy for Kaposi's sarcoma in an HIV-negative patient. Lancet Oncol. 2006;7(10):875-876.
4. Sodhi A, Chaisuparat R, Hu J, et al. The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. Cancer Cell. 2006;10(2):133-143.
5. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002;8(2):128-135.